No annual revenue total was found in Alto Neuroscience, Inc.'s SEC filings.
Alto Neuroscience, Inc. (ANRO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$51.8 million. As of Jun 30, 2026 it held $243.7 million in cash and investments and $20.8 million in total debt.
Revenue
—
Net income (TTM)
$-84.24M
-29.9% vs year-ago TTM
Operating cash flow (TTM)
$-68.28M
-24.0% vs year-ago TTM
Free cash flow (TTM)
$-68.84M
-21.6% vs year-ago TTM
EPS (TTM)
$-2.38
+0.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.95M
+18.0% vs prior year
Net cash
$222.90M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANRO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1999480
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$66.4M | -$68.6M |
| Net income | -$63.2M | -$61.4M |
| Diluted EPS | -$2.19 | -$2.50 |
| Operating cash flow | -$51.8M | -$47.4M |
| Free cash flow | -$51.8M | -$49.5M |
| Total assets | $184.7M | $177.5M |
| Total liabilities | $33.5M | $26.1M |
| Stockholders' equity | $151.1M | $151.5M |
| Cash and investments | $176.5M | $168.2M |
| Total debt | $21.7M | $15.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Officer or director change
|
May 28, 2026 | May 27, 2026 |
All 196 Alto Neuroscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.